Table 2.
Protein expression and genetic aberrations of 732 cases of de novo DLBCL with R-CHOP regimen
| All patients (n=732) | EBV+ (n=28) | EBV− (n=675) | p value | |
|---|---|---|---|---|
| COO class | ||||
| GCB | 370 (51.0%) | 11 (39.3%) | 342 (51.0%) | - |
| ABC | 355 (49.0%) | 17 (60.7%) | 329 (49.0%) | 0.251 |
| CD30 | 118 (16.4%) | 12 (42.9%) | 103 (15.5%) | 0.001 |
| NF-κB | ||||
| p50 | 237 (36.9%) | 15 (65.2%) | 220 (35.9%) | 0.007 |
| p65 | 191 (28.6%) | 7 (25.9%) | 182 (28.8%) | 0.831 |
| c-Rel | 148 (23.2%) | 5 (21.7%) | 139 (22.8%) | 1.000 |
| pSTAT3 | 221 (35.5%) | 13 (56.5%) | 206 (34.9%) | 0.044 |
| BCL2 protein | 359 (49.9%) | 11 (39.3%) | 339 (50.6%) | 0.254 |
| BCL6 protein | 537 (75.1%) | 14 (50.0%) | 507 (76.1%) | 0.003 |
| p53 protein | 260 (36.9%) | 8 (34.8%) | 240 (36.5%) | 1.000 |
| MDM2 protein | 202 (42.3%) | 12 (63.2%) | 179 (40.7%) | 0.059 |
| MDM4 protein | 468 (97.7%) | 18 (94.7%) | 432 (97.7%) | 0.374 |
| Myc protein | 440 (60.9%) | 17 (60.7%) | 413 (61.7%) | 1.000 |
| Myc and BCL2 | 237 (33.0%) | 8 (28.6%) | 225 (33.7%) | 0.685 |
| BCL2 rearrangement | 79 (13.3%) | 1 (5.0%) | 76 (13.4%) | 0.497 |
| BCL6 rearrangement | 120 (25.2%) | 1 (6.3%) | 118 (26.2%) | 0.083 |
| TP53 mutation | 109 (22.0%) | 2 (10.0%) | 102 (22.6%) | 0.271 |
| MDM2 aberration | 3 (0.8%) | 1 (7.1%) | 2 (0.6%) | 0.108 |
| MDM4 aberration | 2 (0.5%) | 1 (7.1%) | 1 (0.3%) | 0.073 |
| MYC rearrangement | 40 (8.4%) | 2 (11.1%) | 38 (8.4%) | 0.660 |
| MYC/BCL2 double* | 11 (1.8%) | 0 (0%) | 11 (1.9%) | 1.000 |
Cutoff for each protein biomarker was found in the “Material and Methods”.
*
Both MYC and BCL2 are rearranged.